Cytrx Corporation

Rush-presbyterian-st. Luke's Medical Center

Liferaft Biosciences, Inc.

Other

Mast Therapeutics, Inc.

Rush Prebyterian-st. Luke Medical Center

Mannarsamy Balasubramanian

R Martin Emanuele

Mark Joseph Newman

Carlos A Rivera-Marrero

Charles William Todd

Robert Newton Brey, Iii

John S Coon

Himanshu Shah

Stewart V Smith

Hameedsulthan S Allaudeen

Daiva K Tautvydas

R Martin Emanuel

StewartV Smith

Provided herein are long circulating material free (LCMF) poloxamer compositions and uses thereof. In particular, provided are LCMF poloxamer 188 compositions and uses thereof. Also provided are supercritical fluid extraction (SFE) methods and high pressure (subcritical) methods for preparing poloxamer compositions, particularly the LCMF poloxamer compositions.

Poloxamer composition free of long circulating material and methods for production and uses thereof

A multi-purpose food grinding machine having an open topped cylindrical vessel that is rotated by a gear reduced motor. The motor is located within a hollow housing. A keyed motor shaft engages a mating aperture in the bottom of the cylinder. A frame holds the housing in place under the vessel. A central shaft is held by the frame and extends downward into the vessel. Rotatable grinding members are attached to the bottom of the shaft so that as the vessel is rotated by the gear motor, the grinding members rotate at the bottom of the vessel causing any food items trapped between the grinding members and the floor of the vessel to be crushed. The grinding members are forced downward by a spring biased mechanism. A spring biased inside wall scraper forces food to drop back down into the vessel.

Multi-purpose food grinding machine

The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymers compositions and compounds. The compositions comprise block copolymers that are useful in gene therapy methods.

Adjuvants and copolymer compositions

The present invention comprises novel polyoxyethylene/polyoxypropylene block copolymer compositions and compounds. The compositions comprise block copolymers that are high molecular weight molecules, and are useful in gene therapy methods.

The present invention includes novel polyoxyethylene/polyoxypropylene block copolymers as well as methods for making the block copolymers. The block copolymers are high molecular weight molecules and are useful as general surfactants and display enhanced biological efficacy as vaccine adjuvants.

Vaccine adjuvant and vaccine method

Vaccine adjuvant and vaccine

The present invention includes compositions and methods using biologically active nonionic reverse block copolymers. The reverse copolymers have an inner core of polyoxypropylene (POP) that is flanked on either end by polyoxyethylene (POE). The reverse block copolymers have the following formula: ##STR1## wherein 'b' represents a number such that the molecular weight of the hydrophobe (C.sub.3 H.sub.6 O).sub.b is between approximately 2,000 and 10,000, and 'a' represents a number such that the percentage of hydrophile (C.sub.2 H.sub.4 O).sub.a is between approximately 5% and 30%. The reverse block copolymers stimulate the immune response, can suppress immune responses such as those in autoimmune diseases, promote the growth of animals, and stimulate hormone production.

Compositions and methods for growth promotion

The present invention comprises methods and compositions for reducing or eliminating multidrug resistance in cancers or certain infections by drug resistant microorganisms in patients. According to the method and composition of the present invention, a non-ionic amphipathic diester of fatty acids or a reverse poloxmer is administered to a patient in which a cancer or microorganism exhibits multidrug resistance to the chemotherapeutic agent. The method and composition of the present invention may be employed with particular efficacy where multidrug resistance to any chemotherapeutic agent has been conferred upon a cancer.

Compositions for reducing multidrug resistance

Methods and compositions for reducing multidrug resistance

The present invention comprises novel preparations of polyoxypropylene/polyoxyethylene copolymers which retain the therapeutic activity of the commercial preparations, but substantially reduce the undesirable effects which are inherent in the prior art preparations. Because the preparations of polyoxypropylene/polyoxyethylene copolymers which comprise the present invention are a less polydisperse population of molecules than the prior art polyoxypropylene/polyoxyethylene copolymers, the biological activity of the copolymers is better defined and more predictable and the cardiotoxicity inherent in the native copolymers is substantially reduced.

Growing community of inventors

Roswell, GA, United States of America

Mannarsamy Balasubramanian